(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 3.13% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Gilead Sciences's revenue in 2025 is $28,735,000,000.On average, 7 Wall Street analysts forecast GILD's revenue for 2025 to be $35,628,816,912,341, with the lowest GILD revenue forecast at $35,282,118,939,169, and the highest GILD revenue forecast at $36,537,930,071,133. On average, 7 Wall Street analysts forecast GILD's revenue for 2026 to be $37,197,731,223,706, with the lowest GILD revenue forecast at $36,191,444,809,841, and the highest GILD revenue forecast at $39,661,436,093,964.
In 2027, GILD is forecast to generate $39,298,535,943,991 in revenue, with the lowest revenue forecast at $38,187,380,085,579 and the highest revenue forecast at $42,170,441,131,021.